If you're looking for unusually high returns on your capital, biotechnology remains a fairly safe bet, even despite its monstrous run-up over the past five years. The growing and aging global population, after all, is expected to drive an ever-increasing demand for the biologically based medicines that are at the very heart of the industry. With this in mind, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) have both proven to be particularly outstanding vehicles to gain exposure to this high-flying industry.